Zealand Pharma A/S (OTCMKTS:ZLDPF) Trading 3.3% Higher

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) traded up 3.3% during trading on Thursday . The stock traded as high as $93.00 and last traded at $92.46. 1,194 shares were traded during trading, a decline of 46% from the average session volume of 2,210 shares. The stock had previously closed at $89.50.

Analyst Ratings Changes

A number of equities research analysts recently commented on ZLDPF shares. BTIG Research began coverage on shares of Zealand Pharma A/S in a report on Thursday, March 7th. They set a “buy” rating on the stock. Cantor Fitzgerald assumed coverage on Zealand Pharma A/S in a report on Tuesday, May 21st. They issued an “overweight” rating on the stock.

Zealand Pharma A/S Stock Performance

The company has a quick ratio of 7.59, a current ratio of 12.30 and a debt-to-equity ratio of 0.10. The business has a 50 day moving average of $89.65 and a two-hundred day moving average of $78.64.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last posted its earnings results on Thursday, May 16th. The company reported ($0.54) earnings per share (EPS) for the quarter. The company had revenue of $2.20 million for the quarter. Zealand Pharma A/S had a negative return on equity of 36.96% and a negative net margin of 213.77%. As a group, equities analysts expect that Zealand Pharma A/S will post -2.54 earnings per share for the current year.

Zealand Pharma A/S Company Profile

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.